5 Investor presentation First three months of 2023 Sales growth of 25% driven by bo Reported geographic sales split for first quarter of 2023 DKK billion 30 Insulin Obesity care 41% 10% GLP-1 Rare disease Other diabetes Growth at CER International Operations 20 18% 10 9% -5% 0 NAO IO EMEA China RoW 1 ‘Other diabetes’ is included in Total IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; RoW: Rest of W Note: Unless otherwise specified, sales growth rates are at CER
Download PDF file